Having identified CD8-C1 cells (the tissue resident CD8+ T cells) and its signature were enriched more in TTs than in PTs, we next examined whether CD8-C1 cells we found will show a better response to anti-PD-1 therapy by using the pretherapy bulk RNA-seq data from a larger cohort of ccRCC patients (CheckMate 025) treated with nivolumab (anti-PD-1) [19, 20]. The gene discussed is CD8A; the disease is nonpapillary renal cell carcinoma.